Unraveling the immunogenetic architecture of cholangiocarcinoma

Cholangiocarcinoma (CCA) is a type of biliary tract cancer (BTC) that remains notoriously aggressive, characterized by profound heterogeneity and conferring a dismal prognosis. Recent advances in genomic profiling have broadened our understanding of its pathogenesis, uncovered targetable tumor somatic alterations, and ushered in an era of precision medicine. These efforts have identified actionable drivers such as FGFR2 fusions, IDH1 mutations, BRAF V600E, and HER2 amplification, for which effective targeted therapies are now available in advanced CCA.1 Against this backdrop, the immunogenetic architecture of CCA and its clinical subtypes has remained relatively poorly defined.2 In this issue of Hepatology, Han et al.3 reported the first large-scale genome-wide association study (GWAS) of CCA and its clinical subtypes, analyzing 2366 cases and 11,750 controls of European ancestry to systematically map inherited susceptibility to this aggressive malignancy. The authors identified 5 new single-nucleotide polymorphisms (SNPs) reaching genome-wide significance (p